Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: A randomized double-blind study

Journal of Clinical Oncology

Volumn 32, Issue 2, 2014, Pages 101-106

  Roila, Fausto ^a   Ruggeri, Benedetta ^b   Ballatori, Enzo ^c   Del Favero, Albano ^d   Tonato, Maurizio ^e  

^a S MARIA HOSPITAL   (Italy)

^b Azienda Sanitaria Unica Regionale Marche   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e Umbria Regional Cancer Network   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APREPITANT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MORPHOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; HEARTBURN; HUMAN; INSOMNIA; MALE; MIDDLE AGED; NAUSEA; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; VERY ELDERLY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEARTBURN; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 84894695465     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.4547     Document Type: Article

References (13)

1. Warr DG, Hesketh PJ, Gralla RJ, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830, 2005 (Pubitemid 46179473)
2. Roila F, Hesketh PJ, Herrstedt J, et al: Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28, 2006 (Pubitemid 43033835)
3. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy: The Italian Group for Antiemetic Research. N Engl J Med 342:1554-1559, 2000
4. Hesketh PJ, Grunberg SM, Gralla RJ, et al: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119, 2003 (Pubitemid 46606178)
5. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098, 2003 (Pubitemid 36676265)
6. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al: Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000-1006, 2006 (Pubitemid 43778994)
7. Lindley CM, Hirsch JD, O'Neill CV, et al: Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331-340, 1992
8. Roila F, Herrstedt J, Aapro M, et al: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol 21:v232-v243, 2010 (suppl 5)
9. Basch E, Prestrud AA, Hesketh PJ, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189-4198, 2011
10. Grunberg S, Chua D, Maru A, et al: Singledose fosaprepitant for the prevention of chemother-apy- induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol - EASE. J Clin Oncol 29:1495-1501, 2011
11. Saito H, Yoshizawa H, Yoshimori K, et al: Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: A multicentre, randomized, double-blind, placebo-controlled phase 3 trial. Ann Oncol 24:1067-1073, 2013
12. Aapro M, Fabi A, Nolè F, et al: Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083-1088, 2010
13. Celio L, Frustaci S, Denaro A, et al: Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: A randomized, multicenter, phase III trial. Support Care Cancer 19:1217-1225, 2011